ATRC
AtriCure, Inc. · Healthcare · Medical - Instruments & Supplies
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 99 | +3 | 35.69M | $1.00B | +9 | −7 |
| Q1 2026 | 100 | +5 | 35.01M | $1.03B | +10 | −6 |
| Q4 2025 | 96 | +1 | 36.16M | $1.43B | +2 | n/a |
| Q3 2025 | 17 | -1 | 19.38M | $683.04M | n/a | −2 |
| Q2 2025 | 16 | -1 | 18.32M | $600.37M | n/a | −1 |
| Q1 2025 | 14 | 0 | 6.98M | $225.02M | +1 | −1 |
| Q4 2024 | 14 | +1 | 5.72M | $174.87M | +2 | −1 |
| Q3 2024 | 12 | -1 | 4.89M | $137.07M | n/a | −1 |
| Q2 2024 | 13 | n/a | 5.61M | $127.65M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 1.54M | n/a | $35.02M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 2 | Geode Capital Management ✦ (passive) | 1.12M | n/a | $25.51M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Millennium Management ✦ | 952.76K | n/a | $21.69M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Two Sigma Investments ✦ | 643.03K | n/a | $14.64M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 447.94K | n/a | $10.20M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Norges Bank ✦ (passive) | 184.31K | n/a | $4.20M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 171.70K | n/a | $3.91M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 153.71K | n/a | $3.50M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 150.00K | n/a | $3.42M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 105.58K | n/a | $2.40M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | AQR Capital Management ✦ | 58.74K | n/a | $1.34M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Bridgewater Associates ✦ | 40.32K | n/a | $918,018 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 39.86K | n/a | $908,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 221 holders, 49.84M shares, $1.41B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.52K sh · $271,140
Director · 5.31K sh · $288,071
Officer · 3.66K sh · $201,135
Officer · 7.76K sh · $407,558
Officer · 9.37K sh · $458,099
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology